The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of patients (pts) with renal cell carcinoma and sarcomatoid dedifferentiation (sRCC) treated with nephrectomy (Nx) and systemic therapies (T) over three decades: The MD Anderson Cancer Center (MDACC) experience.
 
Sarp K. Keskin
No Relationships to Disclose
 
Pavlos Msaouel
No Relationships to Disclose
 
Kenneth R. Hess
Travel, Accommodations, Expenses - Angiochem
 
Surena F. Matin
Consulting or Advisory Role - Theracoat; Tokai Pharmaceuticals
Research Funding - AT&T
 
Eric Jonasch
Consulting or Advisory Role - Cerulean Pharma; Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Onyx; Pfizer
Travel, Accommodations, Expenses - Cerulean Pharma; Novartis; Pfizer
 
Christopher G. Wood
Consulting or Advisory Role - Argos Therapeutics; Novartis; Pfizer
 
Jose A. Karam
Honoraria - Pfizer
Consulting or Advisory Role - Pfizer
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer